The Aminoalkylindole BML-190 Negatively Regulates Chitosan Synthesis via the Cyclic AMP/Protein Kinase A1 Pathway in

Brian T Maybruck1, Woei C Lam1, Charles A Specht2

  • 1Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA.

Mbio
|December 19, 2019
PubMed

Insights

Researchers screened compounds to find new antifungal drugs targeting chitosan production in Cryptococcus neoformans. They identified BML-190, which disrupts the cAMP pathway, reducing chitosan and offering a potential new therapy for this fungal infection.

Area of Science:

  • Mycology
  • Biochemistry
  • Drug Discovery

Background:

  • Cryptococcus neoformans causes fatal meningoencephalitis, particularly in immunocompromised individuals.
  • Current antifungal treatments are suboptimal, necessitating the search for novel therapeutic targets.
  • Chitosan, a key cryptococcal cell wall component, is essential for survival during mammalian host infection.

Purpose of the Study:

  • To identify small-molecule inhibitors of chitosan biosynthesis in C. neoformans.
  • To discover novel antifungal agents by targeting essential cryptococcal cell wall components.
  • To explore new therapeutic strategies against C. neoformans infections.

Main Methods:

  • Developed a cell-based flow cytometry screening method to identify chitosan production inhibitors.
  • Screened the ICCB Known Bioactives library of 480 compounds.
  • Utilized counterscreens, confirmatory screens, and biochemical assays to validate hits.

Main Results:

  • Identified 8 compounds that reduced chitosan production; 2 were confirmed hits.
  • The aminoalkylindole BML-190 was identified as a confirmed hit that reduces chitosan.
  • BML-190 targets the Gpr4 receptor, impacting the cyclic AMP (cAMP)/protein kinase A (PKA) pathway and decreasing chitosan.

Conclusions:

  • The cAMP/PKA signaling pathway regulates chitosan biosynthesis in C. neoformans.
  • The identified screening approach is effective for discovering novel antifungal compounds.
  • BML-190 and its mechanism offer a potential new therapeutic avenue against C. neoformans infections.